Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 10/20 | 0.49 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 6/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810042 | 0.83 | DRD4 (0.51) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL17788488 | 0.83 | HCAR2 (0.46) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL15779863 | 0.81 | DRD4 (0.53) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL15945060 | 0.81 | DRD4 (0.55) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL17273755 | 0.80 | HCAR2 (0.49) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL16867187 | 0.78 | GAA (0.55) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL2241242 | 0.78 | DRD4 (0.53) | TAAR1HCAR2CYP2C9DRD4DRD2 | |
| SCHEMBL20083830 | 0.78 | DRD4 (0.53) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL9608917 | 0.78 | DRD4 (0.55) | HCAR2CYP2C9DRD4DRD2DRD3 | |
| SCHEMBL27968359 | 0.78 | DRD4 (0.55) | HCAR2CYP2C9DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | ATM 3539/4885TAAR1 4242/4885HCAR2 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.